Terms: = Pancreatic cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400
268 results:
1. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang CH; Liu F; Militi S; Hester S; Nibhani R; Deng S; Dunford J; Rendek A; Soonawalla Z; Fischer R; Oppermann U; Pauklin S
Nat Commun; 2024 Apr; 15(1):3580. PubMed ID: 38678032
[TBL] [Abstract] [Full Text] [Related]
2. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
3. PR55α-controlled protein phosphatase 2A inhibits p16 expression and blocks cellular senescence induction by γ-irradiation.
Palanivel C; Madduri LSV; Hein AL; Jenkins CB; Graff BT; Camero AL; Zhou S; Enke CA; Ouellette MM; Yan Y
Aging (Albany NY); 2024 Mar; 16(5):4116-4137. PubMed ID: 38441530
[TBL] [Abstract] [Full Text] [Related]
4. Prox1 Suppresses Proliferation and Drug Resistance of Retinoblastoma Cells via Targeting Notch1.
Zhang HL; Li N; Dong L; Ma HX; Yang MC
Curr Med Sci; 2024 Feb; 44(1):223-231. PubMed ID: 38277016
[TBL] [Abstract] [Full Text] [Related]
5. High-grade Solid Pseudopapillary Neoplasms of the Pancreas: Distinct Clinicopathological Malignant Features With Intriguing Gene Alterations through a Comparison With the Conventional Type.
Honda S; Yamaguchi H; Aimono E; Hara S; Minamiguchi S; Norose T; Ohike N; Yamochi T; Yasuda M; Moriya T; Shiko Y; Nishihara H; Nagao T
Am J Surg Pathol; 2024 Mar; 48(3):353-363. PubMed ID: 38189381
[TBL] [Abstract] [Full Text] [Related]
6. [Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls].
Bräutigam K; Chouchane A; Konukiewitz B; Perren A
Pathologie (Heidelb); 2024 Feb; 45(1):35-41. PubMed ID: 38175232
[TBL] [Abstract] [Full Text] [Related]
7. Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, pancreatic Ductal Adenocarcinoma, and Colorectal cancer.
Boutin R; Lee HF; Guan TL; Nguyen TT; Huang XF; Waller DD; Lu J; Christine Chio II; Michel RP; Sebag M; Tsantrizos YS
J Med Chem; 2023 Dec; 66(23):15776-15800. PubMed ID: 37982711
[TBL] [Abstract] [Full Text] [Related]
8. Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.
Kinowaki Y; Fukumura Y; Kawade G; Sugita K; Kinowaki K; Akahoshi K; Kobayashi M; Ono H; Kudo A; Tanabe M; Akashi T; Ohashi K; Kurata M
Gene; 2024 Jan; 893():147916. PubMed ID: 37866661
[TBL] [Abstract] [Full Text] [Related]
9. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
[TBL] [Abstract] [Full Text] [Related]
10. NET G3 vs NEC: p53 and rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract] [Full Text] [Related]
11. Molecular and Functional Heterogeneity of Primary pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
12. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma.
Mohl DA; Lagies S; Zodel K; Zumkeller M; Peighambari A; Ganner A; Plattner DA; Neumann-Haefelin E; Adlesic M; Frew IJ; Kammerer B
Cells; 2023 Apr; 12(8):. PubMed ID: 37190010
[TBL] [Abstract] [Full Text] [Related]
13. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract] [Full Text] [Related]
14. Integrated Genomic and Clinicopathologic Approach Distinguishes pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract] [Full Text] [Related]
15. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
Yang B; Quan Y; Zhao W; Ji Y; Yang X; Li J; Li Y; Liu X; Wang Y; Li Y
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2169282. PubMed ID: 36656085
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
[TBL] [Abstract] [Full Text] [Related]
17. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant pancreatic cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract] [Full Text] [Related]
18. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY; Zhao L; Van Hummelen P; Martin B; Hornbacker K; Lee H; Xia LC; Padda SK; Ji HP; Kunz P
Endocr Relat Cancer; 2022 Dec; 29(12):665-679. PubMed ID: 36165930
[TBL] [Abstract] [Full Text] [Related]
19. Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma.
Mafficini A; Simbolo M; Shibata T; Hong SM; Pea A; Brosens LA; Cheng L; Antonello D; Sciammarella C; Cantù C; Mattiolo P; Taormina SV; Malleo G; Marchegiani G; Sereni E; Corbo V; Paolino G; Ciaparrone C; Hiraoka N; Pallaoro D; Jansen C; Milella M; Salvia R; Lawlor RT; Adsay V; Scarpa A; Luchini C
Mod Pathol; 2022 Dec; 35(12):1929-1943. PubMed ID: 36056133
[TBL] [Abstract] [Full Text] [Related]
20. Targeting Plk1 Sensitizes pancreatic cancer to Immune Checkpoint Therapy.
Zhang Z; Cheng L; Li J; Qiao Q; Karki A; Allison DB; Shaker N; Li K; Utturkar SM; Atallah Lanman NM; Rao X; Rychahou P; He D; Konieczny SF; Wang C; Shao Q; Evers BM; Liu X
Cancer Res; 2022 Oct; 82(19):3532-3548. PubMed ID: 35950917
[TBL] [Abstract] [Full Text] [Related]
[Next]
